Chronic Lymphocytic Leukemia Treatment Market Research Report: by Type (Indolent & Aggressive), by Treatment (Chemotherapy, Targeted Drug Therapy, Immunotherapy & Bone Marrow Transplant), by End User (Hospitals & Clinics & Others) - Global Forecast Till 2023
Chronic lymphocytic leukemia (CLL) can be referred to as a blood and bone marrow disease that gets adverse gradually. It is considered one of the most common types of leukemia, which generally takes place in adults. It is a type of cancer in which the bone marrow of the patient creates too many lymphocytes and can affect white blood cells, red blood cells, and platelets. The Global Chronic Lymphocytic Leukemia Treatment Market Growth is touted to register a CAGR of 19% during the forecast period (2018-2023).
The surging cases of cancer across the world, faster regulatory approval process, innovative drug therapy, and aggressive pipeline for chronic lymphocytic leukemia treatment drugs are some of the primary growth stimulants of the market. The increasing incidences of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML), coupled with the rising approvals of innovative and novel drugs and immunotherapies are estimated to accelerate the market growth in the foreseeable future.
On the contrary, the stunted level of awareness regarding symptoms will retard the market growth in the years to come. Low accessibility of treatment options, especially in under-developed economies and surging use of generic products are likely to hamper the demand for branded drugs, thereby adversely affecting the market globally.
Chronic Lymphocytic Leukemia Treatment Market Competitive Dashboard
The top players operating in the chronic lymphocytic leukemia treatment market include GlaxoSmithKline plc, Hoffmann-La Roche Ltd, Genmab A/S, CELGENE CORPORATION, Genentech, Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Genzyme Corporation, Novartis AG, Gilead, AstraZeneca, Johnson & Johnson Services, Inc., TG Therapeutics, Inc., ONO PHARMACEUTICAL CO., LTD., and Ziopharm Oncology, Inc.
Global Chronic Lymphocytic Leukemia Treatment Market: Segmental Analysis
The chronic lymphocytic leukemia treatment market has been segmented on the basis of treatment, type, and end user.
By type, the market is segmented into indolent CLL and aggressive CLL.
Based on the treatment, the market is segmented into targeted drug therapy, chemotherapy, bone marrow transplant, and immunotherapy. Of these, targeted drug therapy and immunotherapy are likely to emerge as prominent treatments. The soaring demand for targeted drugs has led to the growth of the segment. Targeted drugs are extensively used due to their low side effects and higher success rates and efficacy when compared to chemotherapy.
The end users segment constitutes of diagnostic laboratories, hospitals & clinics, research institutes, and others. Of these, the hospitals and clinics segment is likely to gain prominence due to the availability of advanced treatment in hospitals and favorable reimbursement policies.
Chronic Lymphocytic Leukemia Treatment Market Regional Frontiers
Geographically, the chronic lymphocytic leukemia treatment market spans across Europe, the Americas, Asia Pacific, and the Middle East & Africa.
Considering the global scenario, the chronic lymphocytic leukemia treatment market is considered to be dominated by the Americas, mainly due to the surging cases of leukemia and the existence of major market players in the region. Over the past few years, there has been tremendous growth in cell-based research activities. The surging research in the field of regenerative medicine for treating leukemia has resulted in the market growth.
Europe bags the second spot, and the regional growth is credited to the increasing R&D activities in the field of leukemia. Massive spending on healthcare, sound healthcare infrastructure, and increased awareness regarding relapse of chronic lymphocytic leukemia and its related treatments are predicted to contribute to the regional market’s growth. The surging use of advanced healthcare equipment, availability of reimbursement policies, and increased adoption of latest technologies are among the major factors likely to accelerate the market’s growth in Europe.
Meanwhile, the Asia Pacific is predicted to expand at the fastest rate due to the mounting demand for treatment of the disease and surging prevalence of leukemia in the region. The hike in R&D activities, coupled with the presence of profitable markets in countries like India, China, Japan, and the Republic of Korea will accelerate the demand from the market. The surging cases of leukemia and its associated treatment options have further led to the expansion of the market.